Détection de la mutation T790M de l'exon 20 du gène EGFR dans le cancer du poumon résistant aux inhibiteurs de l'EGFR sur ADN tumoral circulant (biopsie liquide) / Circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy

DEMANDEUR: Institut universitaire de cardiologie et de pneumologie de Québec Université Laval. OBJECTIF DE L'ANALYSE: L'analyse proposée vise à effectuer la détection de la mutation T790M du gène EGFR (EGFR-T790M) responsable de la résistance aux inhibiteurs de tyrosine kinase (ITK) à partir de l'ADN tumoral circulant d'un patient atteint d'un cancer du poumon non à petites cellules (CPNPC). CONTEXTE DE LA DEMANDE: Approximativement 60 % des patients atteints d'un CPNPC et traités avec un ITK de 1re ou de 2e génération vont développer la mutation de résistance EGFR-T790M et avoir besoin d'un changement thérapeutique. Bien qu'une analyse permettant notamment de détecter cette mutation à partir d'une biopsie tissulaire soit consignée dans le Répertoire québécois et système de mesure des procédures de biologie médicale (ci-après nommé « Répertoire ¼), la présente demande vise à détecter la mutation EGFR-T790M à partir d'échantillons de biopsie liquide, une autre méthode de prélèvement qui permet au patient d'éviter la biopsie tissulaire, les risques qui y sont associés et d'obtenir un changement thérapeutique plus rapidement. NOMBRE D'ANALYSES PRÉVUES: Le demandeur avait originalement prévu que, annuellement, entre 160 et 250 tests seraient nécessaires pour servir la population locale et 2 000 pour l'ensemble du Québec. Or, l'inscription de l'osimertinib en 1re intention de traitement des CPNPC avec mutations activatrices de l'EGFR entraîne une réduction importante du nombre de patients dont l'état nécessitera éventuellement une détection de la mutation EGFRT790M par biopsie liquide selon l'utilisation prévue par le demandeur. Les données de la RAMQ ont révélé que quelques patients continuent de recevoir des ITK de 1re et de 2e génération et sont susceptibles de tirer avantage de cette analyse. MÉTHODOLOGIE: La démarche d'évaluation comprend une revue rapide de la littérature scientifique et grise de même que des consultations menées auprès d'experts et d'autres parties prenantes. Un rapport d'évaluation portant sur la pertinence de recourir à la biopsie liquide dans le même contexte que la présente demande a été publié par Health Quality Ontario (HQO) en mars 2020. Ce rapport comporte une évaluation de la performance diagnostique, de l'utilité clinique, de la sécurité, de l'efficience et de l'impact budgétaire de même qu'une analyse des préférences et des valeurs selon la perspective du patient. Le rapport de HQO a été jugé de bonne qualité méthodologique et constitue la principale source de données de la présente évaluation. L'ensemble des données scientifiques, contextuelles et expérientielles a été interprété et apprécié à l'aide d'une grille-synthèse pour guider le processus de délibération du Comité scientifique des analyses de biologie médicale (CSABM). DONNÉES PUBLIÉES: Performance diagnostique: Selon le rapport d'évaluation de Health Quality Ontario publié en 2020, la concordance des résultats d'une détection de la mutation EGFRT790M entre la biopsie liquide et la biopsie tissulaire varierait de 50 % à 96 %. La sensibilité et la spécificité, la valeur prédictive négative (VPN) et la valeur prédictive positive (VPP) sont respectivement de 68 % [46 % - 88 %], 86 % [62 % - 99 %], 61 % et 89 %. L'utilisation de la droplet digital PCR (ddPCR) augmenterait la fréquence de détection positive de la mutation EGFR-T790M par biopsie liquide. Utilité clinique: HQO n'a repéré aucune donnée sur l'utilisation de la biopsie liquide comme méthode de triage (biopsie liquide + biopsie tissulaire) comparativement à la biopsie tissulaire seule. Toutefois, les études consultées soulignent qu'une fraction des porteurs de la mutation EGFR-T790M (17,8 %) sont identifiés grâce à l'utilisation de la biopsie liquide pour trier les patients résistants aux inhibiteurs des ITK de 1re et 2e génération et pour lesquels la biopsie tissulaire est évitée. En cas de détection de la mutation EGFR-T790M, l'impact sur la prise en charge demeurerait le même quelle que soit la méthode employée car, lorsque la biopsie est positive, le traitement est amorcé. Un gain de survie sans progression de 9,7 mois a été rapporté pour ces deux méthodes. PERSPECTIVE DES PATIENTS: Selon le rapport de HQO, les patients percevraient la biopsie liquide comme une approche plus rapide et plus pratique du fait qu'ils n'auraient pas à attendre plusieurs semaines pour obtenir un rendezvous pour subir une biopsie tissulaire qui pourrait nécessiter un déplacement vers un centre spécialisé plus éloigné. Ils auraient aussi exprimé de la peur et même de la panique relativement au processus de prélèvement de l'échantillon tissulaire qui nécessite une aiguille de gros calibre. POSITIONS ET ORIENTATIONS D'ORGANISMES D'INTÉRÊ: Le National Comprehensive Cancer Network (NCCN) et plusieurs comités d'experts ont recommandé l'utilisation de la biopsie liquide chez un patient qui est médicalement incapable de supporter l'échantillonnage effractif que requiert la biopsie tissulaire. L'ensemble des sociétés savantes recommandent l'utilisation de la biopsie tissulaire lorsque le résultat de la biopsie liquide est négatif. Toutefois, ils soulignent que la biopsie liquide ne devrait pas remplacer la biopsie tissulaire. En revanche, un résultat positif de la biopsie liquide devrait obtenir la même attention qu'un résultat positif de la biopsie tissulaire. ÉVALUATION ÉCONOMIQUE: La biopsie liquide comme méthode de triage est moins coûteuse et plus efficace que la biopsie tissulaire pour détecter la mutation EGFRT790M. Toutefois, lorsqu'on tient compte des avantages cliniques et des coûts liés à l'usage des traitements subséquents, le ratio coûtutilité incrémental est élevé, en raison notamment de l'inefficience de l'osimertinib. Depuis l'inscription aux listes des médicaments de l'osimertinib comme traitement de 1re intention, la population admissible à une biopsie liquide décroît continuellement. Le nombre actuel de personnes qui recevraient des ITK de 1re et 2e génération a été estimé à 32 selon les données de la RAMQ et à 40 en incluant les patients couverts par une assurance privée. Ces analyses estiment les économies de laboratoire à 460 $, mais elles anticipent que 5 patients supplémentaires pourraient recevoir l'osimertinib pour un impact budgétaire net d'environ 537 000 $ au cours des trois prochaines années. POSITION DES EXPERTS CONSULTÉS: Les experts consultés sont favorables à l'utilisation de la biopsie liquide dans le contexte décrit par le demandeur. Ils n'ont pas soulevé d'enjeu en particulier en dehors de la pertinence restreinte de cette analyse étant donné l'inscription récente du traitement osimertinib en 1re intention. L'émergence rapide de nombreuses indications de la biopsie liquide serait imminente et constituerait une révolution technologique et oncologique. ENJEUX PARTICULIERS: Au Québec, l'analyse est principalement employée en contexte de recherche. Des enjeux éthiques et cliniques liés à la biopsie liquide tels que la présence de faux négatifs en raison d'une sensibilité plus faible et la nécessité d'évaluer la survie globale des patients atteints de CPNPC en appliquant cette technique ont également été rapportés dans la littérature. RECOMMANDATION: Suivant une délibération par les membres du CSABM sur l'ensemble de la preuve, y compris la perspective des experts consultés, l'INESSS recommande d'introduire la détection de la mutation EGFR-T790M sur ADN tumoral circulant au Répertoire.

REQUESTER: Institut universitaire de cardiologie et de pneumologie de QuébecUniversité Laval. PURPOSE OF TEST: The test is designed to detect the EGFR gene T790M mutation (EGFRT790M), which is responsible for resistance to tyrosine kinase inhibitors (TKIs), in circulating tumour DNA in non-small cell lung cancer (NSCLC) patients. BACKGROUND TO THE REQUEST: Approximately 60% of NSCLC patients treated with a 1st- or 2ndgeneration TKI will develop the EGFR-T790M resistance mutation and require a change in therapy. Although a test used to detect this mutation from a tissue biopsy is listed in the Répertoire québécois et système de mesure des procédures de biologie médicale (hereinafter the "Répertoire"), the present request concerns the detection of the EGFRT790M mutation in samples obtained by liquid biopsy, an alternative specimen collection method that enables the patient to avoid a tissue biopsy and the associated risks, and to obtain a change in therapy more quickly. EXPECTED NUMBER OF TESTS: The requester had originally anticipated that between 160 and 250 tests would be required annually to serve the local population and 2000 for all of Québec. However, the listing of osimertinib as a 1st-line therapy for NSCLC with EGFR-activating mutations is resulting in a significant reduction in the number of patients who will possibly require EGFRT790M mutation testing by liquid biopsy, based on the use anticipated by the requester. RAMQ data show that a few patients continue to receive 1st- or 2nd-generation TKIs and are likely to benefit from this test. METHODOLOGY: The assessment process included a rapid review of the scientific and grey literature, and consultations with experts and other stakeholders. An assessment report on the relevance of using liquid biopsy in the same context as this request was published by Health Quality Ontario (HQO) in March 2020. The report includes an assessment of its diagnostic performance, clinical utility, safety, cost-effectiveness and budget impact, and an assessment of patient preferences and values. The HQO report was deemed to be of good methodological quality and is the main source of data for the present assessment. All the scientific, contextual and experiential data were interpreted and assessed using a synthesis grid to guide the Comité scientifique des analyses de biologie médicale (CSABM)'s deliberation process. PUBLISHED DATA: Diagnostic performance: According to the Health Quality Ontario assessment report published in 2020, the concordance rate for EGFR-T790M mutation detection results between liquid biopsy and tissue biopsy ranges from 50% to 96%. The sensitivity and specificity, negative predictive value (NPV) and positive predictive value (PPV) are 68% [46%-88%], 86% [62%-99%], 61% and 89%, respectively. The use of droplet digital PCR (ddPCR) appears to increase the rate of positive detection of the EGFR-T790M mutation by liquid biopsy. Clinical utility: HQO did not find any data on the use of liquid biopsy as a triage test (liquid biopsy + tissue biopsy) versus tissue biopsy alone. However, the studies examined note that a proportion of EGFR-T790M mutation carriers (17.8%) are identified through the use of liquid biopsy to detect 1st- or 2nd-generation TKI-resistant patients, who thus avoid a tissue biopsy. If the EGFR-T790M mutation is detected, the impact on management would remain the same, regardless of the method used, because when the biopsy is positive, treatment is initiated. A 9.7-month gain in progression-free survival was reported for both methods. PATIENT PERSPECTIVE: According to the HQO report, patients perceived liquid biopsy as a faster and more convenient approach because they would not have to wait several weeks to get an appointment for a tissue biopsy, which could require a trip to a specialized centre that might be further away. They also expressed fear and even panic about the tissue sample collection procedure, in which a large-gauge needle is used. POSITIONS AND PERSPECTIVES OF ORGANIZATIONS OF INTEREST: The National Comprehensive Cancer Network (NCCN) and a number of expert panels have recommended the use of liquid biopsy in patients who are medically unable to tolerate the invasive specimen collection involved in a tissue biopsy. All the learned societies recommend the use of tissue biopsy when the liquid biopsy result is negative. However, they stress that liquid biopsy should not replace tissue biopsy. In any event, a positive liquid biopsy result should be given the same attention as a positive tissue biopsy result. ECONOMIC EVALUATION: Liquid biopsy as a triage test is less expensive and more effective than tissue biopsy in detecting the EGFR-T790M mutation. However, when the clinical benefits and costs of the subsequent treatments are factored. in, the incremental cost-utility ratio is high, in part because of osimertinib's non-cost-effectiveness. Since the listing of this drug as a 1st-line therapy in the formularies, the liquid biopsy-eligible population has been steadily decreasing. The current number of people receiving 1st- or 2nd-generation TKIs was estimated to be 32, based on RAMQ data, and 40 if patients with private insurance are included. These analyses estimate the laboratory savings at $460, but they anticipate that 5 additional patients could receive osimertinib, for a net budget impact of approximately $537,000 over the next 3 years. POSITION OF THE EXPERTS CONSULTED: The experts consulted support the use of liquid biopsy in the context defined by the requester. They did not raise any specific issues, apart from the limited relevance of this test, given the recent listing of osimertinib as a 1st-line therapy. The rapid emergence of a large number of indications for liquid biopsy appears to be imminent and would constitute a technological and oncologic revolution. SPECIFIC ISSUES: In Québec, liquid biopsy is used primarily in research settings. Ethical and clinical issues associated with this test, such as false negatives due to lower sensitivity and the need to assess overall survival in NSCLC patients in whom this technique is used, have also been reported in the literature. RECOMMENDATION: Based on the deliberation, by the CSABM's members, of all the evidence, including the perspective of the experts consulted, INESSS recommends that circulating tumour DNA-based EGFR-T790M mutation detection be included in the Répertoire

A split NanoLuc complementation-based human norovirus-like particle entry assay facilitates evaluation of anti-norovirus antibodies in live cells.

Human noroviruses (NoVs) are the most common cause of acute gastroenteritis worldwide. One major obstacle in developing NoV vaccines is the lack of robust cell culture for efficacy evaluation. In this study, we successfully developed a NoV virus-like particle (VLP) entry assay based on split NanoLuc luciferase (LgBiT and HiBiT) complementation. HiBiT-tagged NoV GII.4 VLP (VLP-HiBiT) can be efficiently produced in Pichia pastoris and retain binding activity towards NoV receptor histo-blood group antigens (HBGAs). A 293T-FUT2-LgBiT cell line was established and was shown to stably express cell surface HBGAs and intracellular LgBiT. GII.4 VLP-HiBiT can bind and enter into the 293-FUT2-LgBiT cells, producing strong luminescence signals in live cells. Anti-GII.4 sera can inhibit VLP-HiBiT entry into the 293-FUT2-LgBiT cells in a dose-dependent manner, and neutralizing titers well correlate with their blocking titers measured by HBGAs-binding blockade assay. Moreover, such a surrogate infection/neutralization assay can be applied to other NoV genotypes such as GI.1 and GII.17. Together, the VLP-HiBiT entry assay can mimic both NoV attachment and internalization in live cells and thus facilitate reliable and comprehensive evaluation of NoV vaccine and antibodies.

Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.

Pathological mutations in homology-directed repair (HDR) genes impact both future cancer risk and therapeutic options for patients. HDR is a high-fidelity DNA repair pathway for resolving DNA double-strand breaks throughout the genome. BRCA2 is an essential protein that mediates the loading of RAD51 onto resected DNA breaks, a key step in HDR. Germline mutations in BRCA2 are associated with an increased risk for breast, ovarian, prostate, and pancreatic cancer. Clinical findings of germline or somatic BRCA2 mutations in tumors suggest treatment with platinum agents or PARP inhibitors. However, when genetic analysis reveals a variant of uncertain significance (VUS) in the BRCA2 gene, precision medicine-based decisions become complex. VUS are genetic changes with unknown pathological impact. Current statistics indicate that between 10-20% of BRCA sequencing results are VUS, and of these, more than 50% are missense mutations. Functional assays to determine the pathological outcome of VUS are urgently needed to provide clinical guidance regarding cancer risk and treatment options. In this review, we provide a brief overview of BRCA2 functions in HDR, describe how BRCA2 VUS are currently assessed in the clinic, and how genetic and biochemical functional assays could be integrated into the clinical decision process. We suggest a multi-step workflow composed of robust and accurate functional assays to correctly evaluate the potential pathogenic or benign nature of BRCA2 VUS. Success in this precision medicine endeavor will offer actionable information to patients and their physicians.

Mammalian Cell Fusion Assays for the Study of Cell Cycle Progression by Functional Complementation.

Cell cycle progression, or its arrest upon checkpoint activation, is directed by a complex array of cellular processes dependent on the diffusion of chemical signals. These signals regulate the onset of each cell cycle phase and prevent undesired phase transitions. Functional complementation is a robust strategy to identify such signals, by which mutant phenotypes are rescued through complementation with candidate factors. Here we describe a method that reclaims a five-decade old mammalian cell-cell fusion strategy of functional complementation to study the molecular control of cell cycle progression. The generation of cell-cell fusions (heterokaryons) allows for the analysis, via immunofluorescence, of cell cycle regulator dynamics and evaluating the effective rescue of cell cycle progression in specific genetic settings.

A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.

The biosafety level 3 (BSL-3) requirement to culture severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a bottleneck for research. Here, we report a trans-complementation system that produces single-round infectious SARS-CoV-2 that recapitulates authentic viral replication. We demonstrate that the single-round infectious SARS-CoV-2 can be used at BSL-2 laboratories for high-throughput neutralization and antiviral testing. The trans-complementation system consists of two components: a genomic viral RNA containing ORF3 and envelope gene deletions, as well as mutated transcriptional regulator sequences, and a producer cell line expressing the two deleted genes. Trans-complementation of the two components generates virions that can infect naive cells for only one round but does not produce wild-type SARS-CoV-2. Hamsters and K18-hACE2 transgenic mice inoculated with the complementation-derived virions exhibited no detectable disease, even after intracranial inoculation with the highest possible dose. Thus, the trans-complementation platform can be safely used at BSL-2 laboratories for research and countermeasure development.

Escherichia coli FabG 3-ketoacyl-ACP reductase proteins lacking the assigned catalytic triad residues are active enzymes.

The FabG 3-ketoacyl-acyl carrier protein (ACP) reductase of Escherichia coli has long been thought to be a classical member of the short-chain alcohol dehydrogenase/reductase (SDR) family. FabG catalyzes the essential 3-ketoacyl-ACP reduction step in the FAS II fatty acid synthesis pathway. Site-directed mutagenesis studies of several other SDR enzymes has identified three highly conserved amino acid residues, Ser, Tyr, and Lys, as the catalytic triad. Structural analyses of E. coli FabG suggested the triad S138-Y151-K155 to form a catalytically competent active site. To test this hypothesis, we constructed a series of E. coli FabG mutants and tested their 3-ketoacyl-ACP reductase activities both in vivo and in vitro. Our data show that plasmid-borne FabG mutants, including the double and triple mutants, restored growth of E. coli and Salmonella enterica fabG temperature-sensitive mutant strains under nonpermissive conditions. In vitro assays demonstrated that all of the purified FabG mutant proteins maintained fatty acid synthetic ability, although the activities of the single mutant proteins were 20% to 50% lower than that of wildtype FabG. The S138A, Y151F, and K155A residue substitutions were confirmed by tandem mass spectral sequencing of peptides that spanned all three residues. We conclude that FabG is not a classical short-chain alcohol dehydrogenase/reductase, suggesting that an alternative mode of 3-ketoacyl-ACP reduction awaits discovery.

Genetic Manipulation of Corynebacterium diphtheriae and Other Corynebacterium Species.

This article describes several established approaches for genetic manipulation of Corynebacterium diphtheriae, the causative agent of diphtheria that is known to have provided key evidence for Koch's postulates on the germ theory. First, it includes a detailed gene deletion method that generates nonpolar, in-frame, markerless deletion mutants, utilizing the levansucrase SacB as a counter-selectable marker. Second, it provides a thorough protocol for rescuing deletion mutants using Escherichia coli-Corynebacterium shuttle vectors. Finally, a Tn5 transposon mutagenesis procedure is described. In principle, these protocols can be used for other Corynebacterium species, including Corynebacterium glutamicum and Corynebacterium matruchotii. © 2020 Wiley Periodicals LLC Basic Protocol 1: Gene deletion in Corynebacterium diphtheriae Basic Protocol 2: Complementation of a mutant strain Basic Protocol 3: Tn5 transposon mutagenesis of Corynebacterium diphtheriae.

An efficient ORF selection system for DNA fragment libraries based on split beta-lactamase complementation.

PCR-based amplification of annotated genes has allowed construction of expression clones at genome-scale using classical and recombination-based cloning technologies. However, genome-scale expression and purification of proteins for down-stream applications is often limited by challenges such as poor expression, low solubility, large size of multi-domain proteins, etc. Alternatively, DNA fragment libraries in expression vectors can serve as the source of protein fragments with each fragment encompassing a function of its whole protein counterpart. However, the random DNA fragmentation and cloning result in only 1 out of 18 clones being in the correct open-reading frame (ORF), thus, reducing the overall efficiency of the system. This necessitates the selection of correct ORF before expressing the protein fragments. This paper describes a highly efficient ORF selection system for DNA fragment libraries, which is based on split beta-lactamase protein fragment complementation. The system has been designed to allow seamless transfer of selected DNA fragment libraries into any downstream vector systems using a restriction enzyme-free cloning strategy. The strategy has been applied for the selection of ORF using model constructs to show near 100% selection of the clone encoding correct ORF. The system has been further validated by construction of an ORF-selected DNA fragment library of 30 genes of M. tuberculosis. Further, we have successfully demonstrated the cytosolic expression of ORF-selected protein fragments in E. coli.

Genetic Manipulation and Virulence Assessment of Fusobacterium nucleatum.

Considered a commensal, the Gram-negative anaerobe Fusobacterium nucleatum is a key member of the oral microbiome due to its wide range of interactions with many oral microbes. While the periodontal pathogenic properties of this organism have widely been examined, its connotation with extra-oral infections, including preterm birth and colorectal cancer, has now become apparent. Nonetheless, little is known about the mechanisms of pathogenicity and the associated virulence factors of F. nucleatum, most likely due to limited genetic tools and facile methodology. Here, we describe molecular techniques for the genetic manipulation of F. nucleatum, including markerless, nonpolar gene deletion, complementation, and Tn5 transposon mutagenesis. Further, we provide methodology to assess virulence potential of F. nucleatum using a mouse model of preterm birth. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Generation of a galK mutant strain Basic Protocol 2: Complementation of a mutant strain Basic Protocol 3: Tn5 transposon mutagenesis of F. nucleatum Basic Protocol 4: Mouse model of preterm birth.

A proactive genotype-to-patient-phenotype map for cystathionine beta-synthase.

BACKGROUND: For the majority of rare clinical missense variants, pathogenicity status cannot currently be classified. Classical homocystinuria, characterized by elevated homocysteine in plasma and urine, is caused by variants in the cystathionine beta-synthase (CBS) gene, most of which are rare. With early detection, existing therapies are highly effective. METHODS: Damaging CBS variants can be detected based on their failure to restore growth in yeast cells lacking the yeast ortholog CYS4. This assay has only been applied reactively, after first observing a variant in patients. Using saturation codon-mutagenesis, en masse growth selection, and sequencing, we generated a comprehensive, proactive map of CBS missense variant function. RESULTS: Our CBS variant effect map far exceeds the performance of computational predictors of disease variants. Map scores correlated strongly with both disease severity (Spearman's ϱ = 0.9) and human clinical response to vitamin B6 (ϱ = 0.93). CONCLUSIONS: We demonstrate that highly multiplexed cell-based assays can yield proactive maps of variant function and patient response to therapy, even for rare variants not previously seen in the clinic.

Efficient algorithms to discover alterations with complementary functional association in cancer.

Recent large cancer studies have measured somatic alterations in an unprecedented number of tumours. These large datasets allow the identification of cancer-related sets of genetic alterations by identifying relevant combinatorial patterns. Among such patterns, mutual exclusivity has been employed by several recent methods that have shown its effectiveness in characterizing gene sets associated to cancer. Mutual exclusivity arises because of the complementarity, at the functional level, of alterations in genes which are part of a group (e.g., a pathway) performing a given function. The availability of quantitative target profiles, from genetic perturbations or from clinical phenotypes, provides additional information that can be leveraged to improve the identification of cancer related gene sets by discovering groups with complementary functional associations with such targets. In this work we study the problem of finding groups of mutually exclusive alterations associated with a quantitative (functional) target. We propose a combinatorial formulation for the problem, and prove that the associated computational problem is computationally hard. We design two algorithms to solve the problem and implement them in our tool UNCOVER. We provide analytic evidence of the effectiveness of UNCOVER in finding high-quality solutions and show experimentally that UNCOVER finds sets of alterations significantly associated with functional targets in a variety of scenarios. In particular, we show that our algorithms find sets which are better than the ones obtained by the state-of-the-art method, even when sets are evaluated using the statistical score employed by the latter. In addition, our algorithms are much faster than the state-of-the-art, allowing the analysis of large datasets of thousands of target profiles from cancer cell lines. We show that on two such datasets, one from project Achilles and one from the Genomics of Drug Sensitivity in Cancer project, UNCOVER identifies several significant gene sets with complementary functional associations with targets. Software available at: https://github.com/VandinLab/UNCOVER.

Real-Time Genetic Compensation Defines the Dynamic Demands of Feedback Control.

Biological signaling networks use feedback control to dynamically adjust their operation in real time. Traditional static genetic methods such as gene knockouts or rescue experiments can often identify the existence of feedback interactions but are unable to determine what feedback dynamics are required. Here, we implement a new strategy, closed-loop optogenetic compensation (CLOC), to address this problem. Using a custom-built hardware and software infrastructure, CLOC monitors, in real time, the output of a pathway deleted for a feedback regulator. A minimal model uses these measurements to calculate and deliver-on the fly-an optogenetically enabled transcriptional input designed to compensate for the effects of the feedback deletion. Application of CLOC to the yeast pheromone response pathway revealed surprisingly distinct dynamic requirements for three well-studied feedback regulators. CLOC, a marriage of control theory and traditional genetics, presents a broadly applicable methodology for defining the dynamic function of biological feedback regulators.

Genetic Manipulation of Cryptococcus neoformans.

Cryptococcus neoformans is an opportunistic fungal pathogen, which causes life-threatening meningoencephalitis in immunocompromised individuals and is responsible for more than 1,000,000 infections and 600,000 deaths annually worldwide. Nevertheless, anti-cryptococcal therapeutic options are limited, mainly because of the similarity between fungal and human cellular structures. Owing to advances in genetic and molecular techniques and bioinformatics in the past decade, C. neoformans, belonging to the phylum basidiomycota, is now a major pathogenic fungal model system. In particular, genetic manipulation is the first step in the identification and characterization of the function of genes for understanding the mechanisms underlying the pathogenicity of C. neoformans. This unit describes protocols for constructing target gene deletion mutants using double-joint (DJ) PCR, constitutive overexpression strains using the histone H3 gene promoter, and epitope/fluorescence protein-tagged strains in C. neoformans. © 2018 by John Wiley & Sons, Inc.

Are natural proteins special? Can we do that?

Natural proteins represent a minuscule fraction of possible sequence space. These very rare sequences display remarkable properties: They fold into many different stable structures, and perform a wide range of complex biological functions. These two considerations-rarity and functionality-may suggest that natural proteins are somehow special. Is this true? We address this question by exploring attempts to recapitulate the special structures and functions of natural proteins into sequences designed de novo.

Persistence of an Oncogenic Papillomavirus Genome Requires cis Elements from the Viral Transcriptional Enhancer.

Human papillomavirus (HPV) genomes are replicated and maintained as extrachromosomal plasmids during persistent infection. The viral E2 proteins are thought to promote stable maintenance replication by tethering the viral DNA to host chromatin. However, this has been very difficult to prove genetically, as the E2 protein is involved in transcriptional regulation and initiation of replication, as well as its assumed role in genome maintenance. This makes mutational analysis of viral trans factors and cis elements in the background of the viral genome problematic and difficult to interpret. To circumvent this problem, we have developed a complementation assay in which the complete wild-type HPV18 genome is transfected into primary human keratinocytes along with subgenomic or mutated replicons that contain the minimal replication origin. The wild-type genome provides the E1 and E2 proteins in trans, allowing us to determine additional cis elements that are required for long-term replication and partitioning of the replicon. We found that, in addition to the core replication origin (and the three E2 binding sites located therein), additional sequences from the transcriptional enhancer portion of the URR (upstream regulatory region) are required in cis for long-term genome replication.IMPORTANCE Human papillomaviruses infect cutaneous and mucosal epithelial cells of the host, and this results in very-long-lived, persistent infection. The viral genomes are small, circular, double-stranded DNA molecules that replicate extrachromosomally in concert with cellular DNA. This replication strategy requires that the virus has a robust mechanism to partition and retain the viral genomes in dividing cells. This has been difficult to study, because viral transcription, replication, and partitioning are regulated by the same viral proteins and involve overlapping elements in the viral genome. We developed a complementation assay that allows us to separate these functions and define the elements required for long-term replication and stable maintenance replication of the HPV genome. This has important implications, as disruption of viral maintenance replication can eliminate viral genomes from infected cells, thus curing persistent HPV infection.

Optimizing the fragment complementation of APEX2 for detection of specific protein-protein interactions in live cells.

Dynamic protein-protein interactions (PPIs) play crucial roles in cell physiological processes. The protein-fragment complementation (PFC) assay has been developed as a powerful approach for the detection of PPIs, but its potential for identifying protein interacting regions is not optimized. Recently, an ascorbate peroxidase (APEX2)-based proximity-tagging method combined with mass spectrometry was developed to identify potential protein interactions in live cells. In this study, we tested whether APEX2 could be employed for PFC. By screening split APEX2 pairs attached to FK506-binding protein 12 (FKBP) and the FKBP12-rapamycin binding (FRB) domain, which interact with each other only in the presence of rapamycin, we successfully obtained an optimized pair for visualizing the interaction between FRB and FKBP12 with high specificity and sensitivity in live cells. The robustness of this APEX2 pair was confirmed by its application toward detecting the STIM1 and Orial1 homodimers in HEK-293 cells. With a subsequent mass spectrometry analysis, we obtained five different biotinylated sites that were localized to the known interaction region on STIM1 and were only detected when the homodimer formed. These results suggest that our PFC pair of APEX2 provides a potential tool for detecting PPIs and identifying binding regions with high specificity in live cells.

Complete auxotrophy for unsaturated fatty acids requires deletion of two sets of genes in Mycobacterium smegmatis.

The synthesis of unsaturated fatty acids in Mycobacterium smegmatis is poorly characterized. Bioinformatic analysis revealed four putative fatty acid desaturases in its genome, one of which, MSMEG_1886, is highly homologous to desA3, the only palmitoyl/stearoyl desaturase present in the Mycobacterium tuberculosis genome. A MSMEG_1886 deletion mutant was partially auxotrophic for oleic acid and viable at 37°C and 25°C, although with a long lag phase in liquid medium. Fatty acid analysis suggested that MSMEG_1886 is a palmitoyl/stearoyl desaturase, as the synthesis of palmitoleic acid was abrogated, while oleic acid contents dropped by half in the mutant. Deletion of the operon MSMEG_1741-1743 (highly homologous to a Pseudomonas aeruginosa acyl-CoA desaturase) had little effect on growth of the parental strain; however the double mutant MSMEG_1886-MSMEG_1741-1743 strictly required oleic acid for growth. The ΔMSMEG_1886-ΔMSMEG_1741 double mutant was able to grow (poorly but better than the ΔMSMEG_1886 single mutant) in solid and liquid media devoid of oleic acid, suggesting a repressor role for ΔMSMEG_1741. Fatty acid analysis of the described mutants suggested that MSMEG_1742-43 desaturates C18:0 and C24:0 fatty acids. Thus, although the M. smegmatis desA3 homologue is the major player in unsaturated fatty acid synthesis, a second set of genes is also involved.

The AMT1 family genes from Malus robusta display differential transcription features and ammonium transport abilities.

Ammonium is an important nitrogen sources for plant growth. In this study, we report on the gene characterization of the ammonium transporter AMT1 subfamily in the apple rootstock Malus robusta Rehd. Thirteen AMT genes were comprehensively evaluated from the apple genome (version 1.0). Then the gene features and expression patterns of five AMT1 members from M. robusta were analyzed. These genes fell into four clusters in the AMT phylogenetic tree: clade I (MrAMT1;1 and MrAMT1;3), clade II (MrAMT1;4), clade III (MrAMT1;2), and clade IV (MrAMT1;5). All the AMT1s, apart from MrAMT1;4, were expressed in vegetative organs and strongly responded to nitrogen concentration changes. For example, MrAMT1;2 and MrAMT1;3 had high transcript accumulation levels in the leaves and roots, respectively. Finally, the functions of these AMT1s were studied in detail by heterologous expression in yeast. These genes allowed strain 31019b to assimilate nitrogen, but their 15NH4+ uptake kinetics varied. These results revealed the functional roles of AMT1 during ammonium absorption in the AMT-defective mutant yeast system.

Reciprocal complementation of bovine parainfluenza virus type 3 lacking either the membrane or fusion gene.

Two defective bovine parainfluenza virus type 3 (BPIV3) strains were generated, one lacking the membrane (M) protein gene and expressing EGFP (ΔM-EGFP) and the other lacking the fusion (F) protein gene and expressing mStrawberry (ΔF-mSB), by supplying deficient proteins in trans. When Madin-Darby bovine kidney (MDBK) cells were co-infected with ΔM-EGFP and ΔF-mSB at a multiplicity of infection (MOI) of 0.1, complemented viruses were easily obtained. Complemented viruses grew as efficiently as wild-type BPIV3 and could be passaged in MDBK cell cultures even at an MOI of 0.01, possibly due to multiploid virus particles containing genomes of both ΔM-EGFP and ΔF-mSB. This reciprocal complementation method using two defective viruses would be useful to express large or multiple proteins in cell cultures using paramyxovirus vectors.